Many say trend could lead to concerns on manufacturing quality in Indian facilities.
Through messages via the BSNL network, the ministry plans to spread awareness among the public and ask people not to invest in suspicious companies.
National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.
Major hospital chains such as Max Healthcare, Apollo and Fortis are going online in a big way, to extend their operations into smaller towns and cities.
Not far back, in 2010, SRL Diagnostics, promoted by former Ranbaxy promoters Malvinder and Shivinder Singh, acquired the diagnostic services business of Piramal Healthcare for Rs 600 crore (Rs 6 billion).
Department of Pharmaceuticals asks NPPA to review Eli Lilly product prices.
On Monday, the Appellate Board upheld the compulsory licence granted to domestic firm Natco Pharma last year, against Bayer's patented anti-cancer drug Nexavar.
The panel of representatives from various ministries and chaired by B K Singh, director, department of pharmaceuticals, has suggested the government negotiate prices of patented medicines based on reference prices of such drugs in other countries such as Britain, Canada, France, Australia and New Zealand.
While the office of the Drugs Controller General of India is still struggling to accumulate data, compensation had been paid only in 50 per cent of the clinical trial death cases so far, sources said.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
Charge relates to misuse of dominant position to sell spare parts at high rates.
Newly appointed president of the Delhi unit of the Bharatiya Janata Party Vijay Goel tells Gyan Varma that the party would replicate Gujarat's development model in Delhi if it comes to power
No ethics committee shall review and accord its approval to a clinical trial protocol without prior registration with the licensing authority, as defined in clause (b) of rule 21.
He has spoken to the party's heads in the Lok Sabha and the Rajya Sabha, Sushma Swaraj and Arun Jaitley, respectively , to seek support for the two items of proposed legislation. He got no assurance.
Disappointed with past experience, domestic majors even skip giving any memorandum.
Regulator mentions Wockhardt as manufacturer but firm says it only markets drug.
The patent office said Pfizer's claimed patent for Sutent, a cancer drug, did not involve any inventive step.
Health & family welfare ministry's proposal seeks to restrict sale of antibiotics to check self-medication.
The allocations followed two stages.
Prodded by patent cliff & increasing competition, it files application for foray into injectible oncology segment.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances